Who are bupropion + lozenge's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combination Bupropion + NRTs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupropion-lozenge.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

bupropion + lozenge — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bupropion + lozenge (bupropion + lozenge) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidepressant + nicotine replacement therapy. Area: Smoking Cessation / Addiction Medicine.

marketed Antidepressant + nicotine replacement therapy Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

bupropion + lozenge (bupropion + lozenge) — University of Wisconsin, Madison. Bupropion inhibits norepinephrine and dopamine reuptake to reduce nicotine cravings, while the lozenge delivers nicotine to ease withdrawal symptoms during smoking cessation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupropion + lozenge TARGET	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidepressant + nicotine replacement therapy class)

University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupropion + lozenge — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion-lozenge. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing